KDR and neoplasm: These drugs primarily target critical receptors involved in angiogenesis, such as Vascular Endothelial Growth Factor Receptor (VEGFR) and Platelet-Derived Growth Factor Receptor (PDGFR), to inhibit tumor vascularization and growth [12].